InNexus Biotechnology and Genhelix Biopharmaceutical Co. have signed a Letter of Intent to set the stage for a planned strategic collaboration to focus on developing novel antibodies engineered with InNexus’ DXL technology. The research and licensing agreement between the collaborators is expected to be completed later this year. InNexus will conduct preclinical development for a DXL therapeutic against an undisclosed target, with Genhelix providing GMP production and commercial manufac...